JPH06507405A - ピロリジノン類 - Google Patents

ピロリジノン類

Info

Publication number
JPH06507405A
JPH06507405A JP4511481A JP51148192A JPH06507405A JP H06507405 A JPH06507405 A JP H06507405A JP 4511481 A JP4511481 A JP 4511481A JP 51148192 A JP51148192 A JP 51148192A JP H06507405 A JPH06507405 A JP H06507405A
Authority
JP
Japan
Prior art keywords
formula
compound
substituted
hydrogen
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4511481A
Other languages
English (en)
Japanese (ja)
Inventor
ベンダー，ポール・エリオット
クリステンセン，ジークフリート・ベンジャミン，ザ・フォース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JPH06507405A publication Critical patent/JPH06507405A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP4511481A 1991-05-02 1992-05-01 ピロリジノン類 Pending JPH06507405A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69462491A 1991-05-02 1991-05-02
US694,624 1991-05-02
PCT/US1992/003613 WO1992019594A1 (en) 1991-05-02 1992-05-01 Pyrrolidinones

Publications (1)

Publication Number Publication Date
JPH06507405A true JPH06507405A (ja) 1994-08-25

Family

ID=24789624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4511481A Pending JPH06507405A (ja) 1991-05-02 1992-05-01 ピロリジノン類

Country Status (10)

Country Link
EP (1) EP0584208A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH06507405A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1067244A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU1917092A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2102106A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE921376A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9202090A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT100441A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1992019594A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA923210B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501888A (ja) * 2000-06-23 2004-01-22 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ ホスホジエステラーゼｉｖ阻害活性を有する薬剤の調製に有用な化合物
JP2004107323A (ja) * 2002-07-26 2004-04-08 Nippon Nohyaku Co Ltd 新規なハロアルキルスルホンアニリド誘導体及び除草剤並びにその使用方法
WO2006041121A1 (ja) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. 慢性皮膚疾患の治療および／または予防剤
WO2006041120A1 (ja) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. 医薬組成物
JP2006523710A (ja) * 2003-04-16 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４インヒビター

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
CA2400368A1 (en) 1992-12-02 1994-06-09 Allen J. Duplantier Catechol diethers as selective pde iv inhibitors
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
TW263495B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1992-12-23 1995-11-21 Celltech Ltd
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
ATE275951T1 (de) * 1993-06-18 2004-10-15 Smithkline Beecham Corp Verfahren zur identifizierung eines pde iv hemmers
DE69430747T2 (de) 1993-07-28 2003-03-06 Aventis Pharma Ltd., West Malling Verbindungen als pde iv und tnf inhibitoren
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
ES2139754T3 (es) * 1993-11-26 2000-02-16 Pfizer 3-fenil-2-isoxazolinas como agentes antiinflamatorios.
CZ283564B6 (cs) * 1993-11-26 1998-05-13 Pfizer Inc. 3-Aryl-2-isoxazolin-5-hydroxamové kyseliny a farmaceutické prostředky na jejich bázi
ATE260911T1 (de) * 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
CA2143143A1 (en) * 1994-03-08 1995-09-09 Toshihiko Tanaka 3-phenylpyrrolidine derivatives
EP0749307A1 (en) * 1994-03-09 1996-12-27 Pfizer Inc. Isoxazoline compounds as 5-lipoxygenase inhibitors
DK0749428T3 (da) * 1994-03-09 1998-11-16 Pfizer Isooxazolinforbindelser som inhibitorer af TNF-frigivelse
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
EP0758233B1 (en) * 1994-04-21 2003-12-03 Schering Aktiengesellschaft Pde iv inhibitors for treating multiple sclerosis
EP1380291A1 (en) * 1994-04-21 2004-01-14 Schering Aktiengesellschaft PDE IV inhibitors for treating multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US5665737B1 (en) * 1994-10-12 1999-02-16 Euro Celtique Sa Substituted benzoxazoles
JPH10508032A (ja) * 1994-12-13 1998-08-04 ユーロ−セルティーク，エス．エイ． アリールチオキサンチン類
AU706159B2 (en) * 1995-02-10 1999-06-10 Schering Aktiengesellschaft Pharmaceutical preparations for TNF inhibition
US6268373B1 (en) 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
DE19540475A1 (de) * 1995-10-20 1997-04-24 Schering Ag Chirale Methylphenyloxazolidinone
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
EA002274B1 (ru) * 1996-06-25 2002-02-28 Пфайзер Инк. Призводные замещенного индазола и их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и фактора некроза опухоли (фно)
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
KR19980074060A (ko) * 1997-03-21 1998-11-05 김윤배 신규한 치환된 3,4-디알콕시페닐 유도체
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US6376489B1 (en) 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6680336B2 (en) 1999-12-15 2004-01-20 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6348602B1 (en) * 1999-12-23 2002-02-19 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6372777B1 (en) 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
FR2803593B1 (fr) 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
WO2002081447A1 (en) * 2001-04-06 2002-10-17 Daewoong Pharmaceutical Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof
WO2002081446A1 (en) * 2001-04-06 2002-10-17 Daewoong Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof
FR2823748B1 (fr) * 2001-04-20 2004-02-20 Sanofi Synthelabo Tetrahydropyridyl-alkyl-benzodiazines, procede pour leur preparation et compositions pharmaceutiques les contenant
NZ529654A (en) 2001-05-29 2005-12-23 Schering Ag CDK inhibiting pyrimidines, production thereof and their use as medicaments
DE60233884D1 (de) * 2001-10-16 2009-11-12 Memory Pharmaceutical Corp 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
AU2003252259A1 (en) * 2002-07-26 2004-02-16 Nihon Nohyaku Co., Ltd. Novel haloalkylsulfonanilide derivatives, herbicides and usage thereof
ATE425966T1 (de) 2002-11-26 2009-04-15 Pfizer Prod Inc Durch phenyl subtituierten piperidinverbindungen zur verwendung als ppar-aktivatoren
MXPA05011200A (es) 2003-04-18 2005-12-14 Memory Pharm Corp Derivados de pirazol como inhibidores de fosfodiesterasa 4.
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1799673A1 (en) 2004-10-15 2007-06-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
WO2006044955A1 (en) 2004-10-20 2006-04-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
NZ571429A (en) 2006-04-21 2011-09-30 Novartis Ag Purine derivatives for use as adenosine A2A receptor agonists
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
US20080176901A1 (en) 2007-01-10 2008-07-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
PT2231642E (pt) 2008-01-11 2014-03-12 Novartis Ag Pirimidinas como inibidores de quinase
CN102112130A (zh) 2008-06-10 2011-06-29 诺瓦提斯公司 作为上皮钠通道阻滞剂的吡嗪衍生物
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
EA026693B1 (ru) 2009-08-17 2017-05-31 Интелликайн ЭлЭлСи Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
IN2012DN01453A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2009-08-20 2015-06-05 Novartis Ag
WO2011050325A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
PL3134396T3 (pl) 2014-04-24 2020-04-30 Novartis Ag Pochodne aminopirydyny jako inhibitory 3-kinazy fosfatydyloinozytolu
US9862711B2 (en) 2014-04-24 2018-01-09 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
BR112021024668A2 (pt) 2019-06-10 2022-05-31 Novartis Ag Derivado de piridina e pirazina para o tratamento de fc, dpoc e bronquiectasia
BR112022002569A2 (pt) 2019-08-28 2022-07-19 Novartis Ag Derivados de 1,3-fenil heteroarila substituídos e seu uso no tratamento de doenças
CN114558002A (zh) * 2022-03-15 2022-05-31 四川轻化工大学 化合物在制备治疗肿瘤药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1350582A (en) * 1970-07-24 1974-04-18 Ucb Sa Cerivatives of 2-pyrrolidinone
JPS4916872A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1972-04-21 1974-02-14
JPS5238227B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1972-06-14 1977-09-28
JPS5232064B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1972-06-14 1977-08-19
JPS5182258A (ja) * 1974-04-25 1976-07-19 Yoshitomi Pharmaceutical Pirorijinonjudotaino seizoho
US4476311A (en) * 1980-03-12 1984-10-09 The Purdue Frederick Company Analgesic 4-carboxy-pyrrolidin-2-one compound
DE3823299A1 (de) * 1988-07-07 1990-01-11 Schering Ag Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501888A (ja) * 2000-06-23 2004-01-22 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ ホスホジエステラーゼｉｖ阻害活性を有する薬剤の調製に有用な化合物
JP2004107323A (ja) * 2002-07-26 2004-04-08 Nippon Nohyaku Co Ltd 新規なハロアルキルスルホンアニリド誘導体及び除草剤並びにその使用方法
JP2006523710A (ja) * 2003-04-16 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４インヒビター
WO2006041121A1 (ja) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. 慢性皮膚疾患の治療および／または予防剤
WO2006041120A1 (ja) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. 医薬組成物

Also Published As

Publication number Publication date
CA2102106A1 (en) 1992-11-03
ZA923210B (en) 1993-03-31
AU1917092A (en) 1992-12-21
IE921376A1 (en) 1992-11-04
PT100441A (pt) 1993-09-30
WO1992019594A1 (en) 1992-11-12
MX9202090A (es) 1992-11-01
CN1067244A (zh) 1992-12-23
EP0584208A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-03-23
EP0584208A1 (en) 1994-03-02

Similar Documents

Publication Publication Date Title
JPH06507405A (ja) ピロリジノン類
JP3333510B2 (ja) 抗アレルギー、抗炎症および腫瘍壊死因子抑制活性を有するシクロペンタンおよびシクロペンテン誘導体
JPH07508263A (ja) 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物
JPH07508262A (ja) 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物
CZ283425B6 (cs) Fenylové deriváty a farmaceutické prostředky s jejich obsahem
CN106879256B (zh) 2-氨基-苯并咪唑衍生物及其作为5-脂氧合酶和/或前列腺素e合成酶抑制剂的应用
JPH06500071A (ja) 新規化合物類
JPH07508261A (ja) アレルギーおよび炎症疾患の治療用化合物
HUT77002A (hu) Tachikininantagonista vegyületek
JPS61134379A (ja) アミノメチルオキソオキサゾリジニルベンゼン誘導体
JP2002522541A (ja) ホスホジエステラーゼ４阻害剤としての置換１，８−ナフチリジン−４（１ｈ）−オン
JPH09501420A (ja) ３−シアノ−３−（３，４−二置換）フェニルシクロヘキシル−１−カルボキシレート類
JP2002518377A (ja) アリールアルカノイルピリダジン
US12364695B2 (en) Methods of treating inflammatory disease
WO1993007141A1 (en) Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
JPS61167687A (ja) ４，５，６，７−テトラヒドロイミダゾ〔４，５−ｃ〕ピリジン誘導体
JPH09503505A (ja) 化合物、組成物ならびにアレルギーおよび炎症の治療
JPH09503503A (ja) 化合物、組成物ならびにアレルギーおよび炎症の治療
JP2514163B2 (ja) ピリミドン誘導体及び類似化合物を含有する、喘息又は炎症性気道疾患の治療用医薬組成物
US7122543B2 (en) Substituted benzoic acid derivatives having NF-κB inhibiting action
TW200845987A (en) Antibacterial quinoline derivatives
HU184610B (en) Process for producing immunostimulating n-substituted-aziridine-2-carboxylic acid derivatives
JPH11507331A (ja) ４，４−（二置換）シクロヘキサン−１−オール類モノマーおよび関連化合物
AU600994B2 (en) Anti-hyperglycaemic and anti-hypertensive heterocyclic compounds
US4548947A (en) 1-(Substituted-aryl)-dihydro-1H-pyrrolizine-3,5-[2H,6H-]diones and use for reversing amnesia